DAPK1 and chronic myelogenous leukemia, BCR-ABL1 positive: As expected, none of the healthy individuals (control; n=0/25) exhibited a methylated DAPK1 promoter region; however, almost 25% of CML patients (resistant and non-resistant) exhibited DAPK1 methylation (P<0.05; Fig. 1B).